GNLX · GENELUX Corp
$2.55
-0.02 (-0.59%)
At close · Oct 12
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has experienced recurring losses from operations since inception and incurred a net loss of $18.4 million and cash used in operations of $12.5 million during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$115.83M
Shares
45.25M
Volume · Oct 12
72.62K
Avg daily vol (3M)
274.5K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.56
Open$2.48
Day$2.47–2.57
52W close$2.30–8.24
Avg vol 30d261K
Short int4.4M · 9.6% float · 20.4d
Short vol29%
DataJan 2023–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$35.60M
Trailing 12 months
Revenue growth YoY
-95.3%
Year over year
Operating margin
-415,175.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-24.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+18.5%
Year over year · more shares
Price change (1Y)
-54.9%
Trailing year
Short interest
9.6%
Latest settlement · 20.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−9%
below
Price vs 50-day avg
−2%
below
RSI (14)
51
neutral
MACD trend
Positive
52-week position
4%
near low
Momentum
relative strength
1-month return
+3%
trailing
6-month return
−3%
trailing
YTD return
−41%
this year
Relative strength
−13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +11 funds added
Insider flow
Distributing
Net -$159.4K over 90 days · 100% sells
Short interest
Rising
9.64% of float · ▲ +6.5% MoM · 20.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
72 holders — mid 3-yr range
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
0%
Y/Y
EPS growth
+9%
Y/Y
Free cash flow
$-26.4M
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−72%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−9%
Bearish
Price vs 50-day avg
−2%
Neutral
RSI (14)
51
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +11 funds added
Insider flow
Distributing
Net -$159.4K over 90 days · 100% sells
Short interest
Rising
9.64% of float · ▲ +6.5% MoM · 20.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
72 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $3 · 4%
Range high $8
vs 200-day avg -9%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GNLX
this stock
GENELUX Corp
|
$115.83M | -41.3% | +0.0% | — | 9.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.77B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GNLX | +0.0% | +2.8% | -3.4% | +1.2% | -41.3% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -1.2% | +0.9% | -13.3% | -0.9% | -55.5% |